Dallas, TX - As new agents are developed for the treatment of primary pulmonary hypertension (PPH), long-term data are now becoming available on the first drug approved for this indication, ...
Epoprostenol (FLOLAN) is an intravenous medication used to treat primary pulmonary hypertension (PPH), a condition characterized by progressive increases in pulmonary artery pressure, leading to right ...
A 37-year-old G2 P0101 woman with known PAH presented with baseline New York Heart Association or World Health Organization functional class III disease. 10 Previously lost to follow-up, she presented ...
DALLAS, Aug. 27 – Long-term use of a vasodilator drug can significantly increase survival and improve quality of life in patients with primary pulmonary hypertension (PPH), according to the first ...
AbstractTransition from prostacyclin analogue infusion to oral therapy in patients with pulmonary arterial hypertension (PAH) is possible with acceptable short- and midterm results. However, there is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results